
Cyclacel Pharmaceuticals CYCCP
Geschäftsbericht 2025
hinzugefügt 30.03.2026
Cyclacel Pharmaceuticals ROE 2011-2026 | CYCCP
ROE Jährlich Cyclacel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.82 | 515.73 | -3715.82 | -132.99 | -50.69 | -25.39 | -66.94 | -47.72 | -34.32 | -82.61 | -76.15 | -89.39 | -36.23 | -131.61 | -78.17 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 515.73 | -3715.82 | -273.07 |
ROE Vierteljährlich Cyclacel Pharmaceuticals
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 386.94 | 74.83 | 9.27 | -96.8 | -404.63 | -135.8 | -186.36 | -209.45 | -118.53 | -50.53 | -62.59 | -51.55 | -48.27 | -31.16 | -37.94 | -32.67 | -27.32 | -16.96 | -33.22 | -42.68 | -51.42 | -47.24 | -60.78 | -58.07 | -54.96 | -34.5 | -43.03 | -38.02 | -35.94 | -25.72 | -46.36 | -58.47 | -69.2 | -62.72 | -77.1 | -70.85 | -67.84 | -58.23 | -80.86 | -89.1 | -93.52 | -67.26 | -85.12 | -80.35 | -52.84 | -23.53 | -42.39 | -43.4 | -84.43 | -84.06 | -101.73 | -100.53 | -83.04 | -59.41 | -17.67 | -18.22 | -23.53 |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 386.94 | -404.63 | -58.02 |
ROE anderer Aktien in der Pharmaeinzelhändler
| Name | ROE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 9.33 | 1.41 % | $ 603 M | ||
|
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-5.9 | $ 0.87 | -2.13 % | $ 6.4 M | ||
|
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.38 | 0.81 % | $ 3.71 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | ||
|
Galapagos NV
GLPG
|
-11.44 | $ 28.15 | 1.04 % | $ 2.69 B | ||
|
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | ||
|
Grifols, S.A.
GRFS
|
9.2 | $ 8.22 | 3.92 % | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 30.95 | -0.34 % | $ 1.78 B | ||
|
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - | ||
|
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.43 | -0.12 % | $ 76.1 M | ||
|
InflaRx N.V.
IFRX
|
-43.64 | $ 1.97 | -0.51 % | $ 152 M | ||
|
Incyte Corporation
INCY
|
24.9 | $ 98.55 | -0.55 % | $ 19.2 B | ||
|
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.71 | 1.27 % | $ 1.74 M | ||
|
Innoviva
INVA
|
23.12 | $ 22.97 | -0.35 % | $ 1.55 B | ||
|
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
1.11 | $ 104.02 | 2.41 % | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | ||
|
Jaguar Health
JAGX
|
286.68 | $ 7.34 | -6.79 % | $ 17.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | ||
|
KalVista Pharmaceuticals
KALV
|
4039.99 | $ 26.68 | 0.02 % | $ 1.44 B | ||
|
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.45 | -2.68 % | $ 235 M | ||
|
Kamada Ltd.
KMDA
|
9.59 | $ 8.16 | 0.68 % | $ 260 M | ||
|
Krystal Biotech
KRYS
|
16.8 | $ 260.24 | 0.11 % | $ 7.53 B | ||
|
Kazia Therapeutics Limited
KZIA
|
-132.24 | $ 13.58 | 9.34 % | $ 1.8 B | ||
|
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-0.49 | $ 220.06 | -2.13 % | $ 4.02 B | ||
|
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.94 | -1.67 % | $ 4.84 M | ||
|
Liquidia Corporation
LQDA
|
-154.03 | $ 38.41 | 0.67 % | $ 3.31 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | ||
|
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
248.9 | $ 4.08 | 0.62 % | $ 436 M | ||
|
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.15 | 3.49 % | $ 2.95 B |